23:34 , Oct 3, 2018 |  BC Extra  |  Politics & Policy

Phage display founders win Nobel for chemistry

The 2018 Nobel Prize for Chemistry was awarded to three scientists for their work on directed evolution of proteins and enzymes, which led to the development of human antibody-based therapeutics. The first, Humira adalimumab from...
17:57 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

Ahren Innovation Capital LLP (Cambridge, U.K.) announced the first close of its Ahren LP fund with over $100 million from Aviva, Wittington Investments and undisclosed U.S. family offices. The fund declined to disclose the exact...
23:29 , Sep 4, 2018 |  BC Extra  |  Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

Ahren Innovation Capital LLP (Cambridge, U.K.) announced the first close of its Ahren LP fund with over $100 million from Aviva, Wittington Investments and undisclosed U.S. family offices. The fund declined to disclose the exact...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
07:00 , Jul 21, 2016 |  BC Innovations  |  Strategy

Brexit of brains

Few in the British life sciences sector voiced support for an exit from the EU before last month's referendum, but academics, industry leaders and investors are now weighing up the actual damage as they face...
08:00 , Feb 24, 2014 |  BioCentury  |  Tools & Techniques

Bigger is better

X-Chem Inc. has developed a screening platform and library of DNA-encoded small molecules that enable the identification of high-quality lead candidates against difficult targets. So far, the platform has yielded a handful of discovery deals,...
08:00 , Jan 13, 2014 |  BioCentury  |  Product Development

Niche play on TGF beta

Scholar Rock LLC 's first disclosed deal provides a glimpse into how the company thinks it can exploit new structural biology insights about well-trodden growth factor targets to develop new therapies. The biotech has partnered...
07:00 , Oct 21, 2013 |  BioCentury  |  Strategy

MedImmune's warheads

AstraZeneca plc 's latest pair of deals - the acquisition of Spirogen Ltd. and a partnership with ADC Therapeutics S.a.r.l. - gives the pharma's MedImmune LLC biologics unit all the tools it needs for antibody-drug...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Fresolimumab regulatory update

The European Commission granted Orphan Drug designation for fresolimumab from Sanofi's Genzyme Corp. unit to treat focal segmental glomerulosclerosis. The pan-specific human mAb against transforming growth factor (TGF) beta completed a Phase I trial for...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

AstraZeneca, Novartis other news

A judge in the Patents Court of the Chancery Division of the U.K. High Court of Justice ruled that two patents covering a phage display screening method from the MedImmune LLC subsidiary of AstraZeneca are...